A Cure for Multiple Sclerosis? Scientists Say Within Our Lifetime







A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are keeping millions with MS healthier for longer – many disability-free. Now, the university is paving the way for an MS cure in our lifetimes.

But the breakthrough almost didn’t happen. “Biologically implausible,” is what the National Institutes of Health’s rejection letter said. It was the late ’90s and UCSF Neurology Professor Stephen Hauser, MD, and team had applied for federal funding for the first clinical trial of the new medicine, rituximab, as a potential MS treatment.

The study wouldn’t just test a new drug, but a revolutionary new theory about MS’ inner workings. So outlandish was the idea that the largest public funder of scientific research said it couldn’t be done.

The rejection “hit like a ton of bricks,” Hauser remembered in his 2023 memoir, The Face Laughs While the Brain Cries. But if Hauser’s team proposed another trial, following conventional wisdom, the institutes assured him there was money.

The message was clear: “Just forget your last 15 years of work, kid, and do what we think.”
‘I decided right there that this would be my life’s work’


Two decades earlier as a young medical resident, Hauser treated 27-year-old Andrea. A recent Harvard Law graduate, Andrea was a rising star in President Jimmy Carter’s administration. Then, as sudden as a lightning strike, her behavior became erratic. By the time Hauser saw her, she was propped up in a hospital bed, the right side of her mouth drooping, saliva pooling at the corner.

MS is a disease of the brain and immune system. Our brains contain a network of billions of neurons, nerve cells that send messages telling our mouth to speak, our legs to move and our lungs to breathe. Each neuron is wrapped in myelin, a protective coating like the plastic sheath around a copper electrical wire. But with MS, our immune system – which normally protects us against germs – mistakes myelin for a foreign invader. This case of mistaken identity prompts an all-out assault. The immune system attacks the myelin, short-circuiting our neurons like frayed power cords.

Over time, the connections between nerves are lost, nerve cells die. MS robs people of basic functions we take for granted – vision, sensation, motor strength … and sometimes, as with Andrea, even the ability to speak, eat or breathe independently,” Hauser said.

With no effective treatment, there was nothing Hauser could do for Andrea. “I decided right there that this common, crippling disease of young adults would be my life’s work.”

The federal government has to rely on expert referees to guide funding decisions, and it’s very difficult to turn around entrenched ideas, even if there’s all sorts of wonderful biology behind the new idea,” said Hauser, explaining why he understood the NIH’s initial rejection. “And it’s important that the federal government not spend their resources funding new ideas that most experts feel are unlikely to succeed; this protects us all against the use of public funds to advance crackpot ideas.”

Pharmaceutical company Genentech, co-founded by UCSF professors, agreed to fund what would become a wildly successful trial of the drug as an MS treatment. Rituximab stopped the disease virtually in its tracks, changing the face of MS forever. The breakthrough led to the 2017 development of a second MS medicine, ocrelizumab and then a third, ofatumumab, in 2020, also pioneered by Hauser and his UCSF colleagues working closely with industry partners.

“Beautifully, this is a UCSF story but it also involves great colleagues at other centers across the globe, courageous industry leaders and fantastic philanthropists who believed in high-risk work at a time when traditional funding sources would never be able to support this research,” Hauser said. “And finally, without the thousands of patients who trusted in us and were courageous enough to volunteer for these clinical studies, this progress could never have been made.”


Website: International Research Scientist Award


#Professor, #Lecturer, #Scientist, #Scholar, #Researcher, #Analyst, #Engineer, #Technician, #Coordinator, #Specialist, #Writer, #Assistant, #Associate, #Biologist, #Chemist, #Physicist, #Statistician, #DataScientist, #Consultant, #Coordinator, #ResearchScientist, #SeniorScientist, #JuniorScientist, #PostdoctoralResearcher, #LabTechnician, #ResearchCoordinator, #PrincipalInvestigator, #ClinicalResearchCoordinator, #GrantWriter, #R&DManager, #PolicyAnalyst, #TechnicalWriter, #MarketResearchAnalyst, #EnvironmentalScientist, #SocialScientist, #EconomicResearcher, #PublicHealthResearcher, #Anthropologist, #Ecologist, #Geologist

More Details:


Comments

Popular posts from this blog

The research ranks are faculty positions for those who are advancing science within a laboratory or research group at Yale School of Medicine.

Researchers discover a surprising way to jump-start battery performance

Your Guide to Becoming a Successful Research Scientist 2024!